Compugen (CGEN) - Net Assets

Latest as of June 2026: ILA88.06 Million ILA ≈ $236.08K USD

Based on the latest financial reports, Compugen (CGEN) has net assets worth ILA88.06 Million ILA (≈ $236.08K USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA137.31 Million ≈ $368.12K USD) and total liabilities (ILA49.25 Million ≈ $132.04K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CGEN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets ILA88.06 Million
% of Total Assets 64.13%
Annual Growth Rate 8.34%
5-Year Change -3.71%
10-Year Change 61.73%
Growth Volatility 139.03

Compugen - Net Assets Trend (1999–2025)

This chart illustrates how Compugen's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Compugen market capitalisation.

Annual Net Assets for Compugen (1999–2025)

The table below shows the annual net assets of Compugen from 1999 to 2025. Also explore Compugen annual equity growth to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 ILA102.73 Million
≈ $275.42K		 +87.08%
2024-12-31 ILA54.91 Million
≈ $147.22K		 -16.24%
2023-12-31 ILA65.56 Million
≈ $175.76K		 -15.60%
2022-12-31 ILA77.68 Million
≈ $208.26K		 -27.19%
2021-12-31 ILA106.69 Million
≈ $286.04K		 -10.93%
2020-12-31 ILA119.78 Million
≈ $321.13K		 +212.58%
2019-12-31 ILA38.32 Million
≈ $102.74K		 +2.89%
2018-12-31 ILA37.24 Million
≈ $99.85K		 +27.12%
2017-12-31 ILA29.30 Million
≈ $78.54K		 -53.88%
2016-12-31 ILA63.52 Million
≈ $170.29K		 -29.34%
2015-12-31 ILA89.90 Million
≈ $241.01K		 -15.17%
2014-12-31 ILA105.97 Million
≈ $284.12K		 +232.34%
2013-12-31 ILA31.89 Million
≈ $85.49K		 +80.44%
2012-12-31 ILA17.67 Million
≈ $47.38K		 -9.75%
2011-12-31 ILA19.58 Million
≈ $52.50K		 -30.77%
2010-12-31 ILA28.29 Million
≈ $75.83K		 +3.24%
2009-12-31 ILA27.40 Million
≈ $73.45K		 +173.90%
2008-12-31 ILA10.00 Million
≈ $26.82K		 -42.13%
2007-12-31 ILA17.29 Million
≈ $46.34K		 -32.84%
2006-12-31 ILA25.74 Million
≈ $69.00K		 -28.99%
2005-12-31 ILA36.25 Million
≈ $97.18K		 -26.87%
2004-12-31 ILA49.57 Million
≈ $132.88K		 -17.12%
2003-12-31 ILA59.81 Million
≈ $160.34K		 -13.17%
2002-12-31 ILA68.88 Million
≈ $184.67K		 -13.97%
2001-12-31 ILA80.06 Million
≈ $214.64K		 -13.46%
2000-12-31 ILA92.51 Million
≈ $248.02K		 +623.47%
1999-12-31 ILA12.79 Million
≈ $34.28K		 --

Equity Component Analysis

This analysis shows how different components contribute to Compugen's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 43849799900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock ILA262.00K 0.26%
Other Comprehensive Income ILA8.00K 0.01%
Other Components ILA555.88 Million 541.10%
Total Equity ILA102.73 Million 100.00%

Compugen Competitors by Market Cap

The table below lists competitors of Compugen ranked by their market capitalization.

Company Market Cap
Berjaya Assets Bhd
KLSE:3239
 $186.27 Million
Melar Acquisition Corp. I Unit
NASDAQ:MACIU
 $186.30 Million
Savior Lifetec
TWO:4167
 $186.32 Million
Inversora Juramento SA
BA:INVJ
 $186.35 Million
Saraswanti Anugerah Makmur Pt
JK:SAMF
 $186.19 Million
TIL Limited
NSE:TIL
 $186.10 Million
HIL Limited
NSE:HIL
 $186.09 Million
ZHOU HEI YA HLDG -000001
F:ZHY
 $186.07 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Compugen's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 54,914,000 to 102,730,999, a change of 47,816,999 (87.1%).
  • Net income of 35,342,999 contributed positively to equity growth.
  • New share issuances of 10,535,000 increased equity.
  • Other comprehensive income decreased equity by 3,001.
  • Other factors increased equity by 1,942,001.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ILA35.34 Million +34.4%
Share Issuances ILA10.54 Million +10.25%
Other Comprehensive Income ILA-3.00K -0.0%
Other Changes ILA1.94 Million +1.89%
Total Change ILA- 87.08%

Book Value vs Market Value Analysis

This analysis compares Compugen's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 670.66x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 809.98x to 670.66x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1999-12-31 ILA0.91 ILA734.40 x
2000-12-31 ILA6.65 ILA734.40 x
2001-12-31 ILA3.08 ILA734.40 x
2002-12-31 ILA2.64 ILA734.40 x
2003-12-31 ILA2.26 ILA734.40 x
2004-12-31 ILA1.80 ILA734.40 x
2005-12-31 ILA1.31 ILA734.40 x
2006-12-31 ILA0.92 ILA734.40 x
2007-12-31 ILA0.61 ILA734.40 x
2008-12-31 ILA0.35 ILA734.40 x
2009-12-31 ILA0.96 ILA734.40 x
2010-12-31 ILA0.85 ILA734.40 x
2011-12-31 ILA0.57 ILA734.40 x
2012-12-31 ILA0.49 ILA734.40 x
2013-12-31 ILA0.82 ILA734.40 x
2014-12-31 ILA2.19 ILA734.40 x
2015-12-31 ILA1.78 ILA734.40 x
2016-12-31 ILA1.25 ILA734.40 x
2017-12-31 ILA0.57 ILA734.40 x
2018-12-31 ILA0.67 ILA734.40 x
2019-12-31 ILA0.60 ILA734.40 x
2020-12-31 ILA1.50 ILA734.40 x
2021-12-31 ILA1.27 ILA734.40 x
2022-12-31 ILA0.92 ILA734.40 x
2023-12-31 ILA0.75 ILA734.40 x
2024-12-31 ILA0.61 ILA734.40 x
2025-12-31 ILA1.10 ILA734.40 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Compugen utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 34.40%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 48.57%
  • • Asset Turnover: 0.46x
  • • Equity Multiplier: 1.53x
  • Recent ROE (34.40%) is above the historical average (-41.83%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1999 -63.57% -251.13% 0.21x 1.21x ILA-9.41 Million
2000 -14.49% -194.51% 0.07x 1.06x ILA-22.66 Million
2001 -18.92% -133.31% 0.13x 1.09x ILA-23.15 Million
2002 -17.72% -109.98% 0.14x 1.12x ILA-19.09 Million
2003 -19.13% -129.64% 0.13x 1.13x ILA-17.42 Million
2004 -27.68% -340.75% 0.07x 1.12x ILA-18.68 Million
2005 -38.56% -2163.78% 0.02x 1.16x ILA-17.60 Million
2006 -50.59% -6055.81% 0.01x 1.20x ILA-15.59 Million
2007 -70.08% -6730.00% 0.01x 1.25x ILA-13.84 Million
2008 -125.23% -3706.21% 0.02x 1.42x ILA-13.53 Million
2009 -13.98% -1532.40% 0.01x 1.10x ILA-6.57 Million
2010 -25.47% -646.01% 0.03x 1.29x ILA-10.03 Million
2011 -61.30% 0.00% 0.00x 1.49x ILA-13.96 Million
2012 -77.12% -5631.40% 0.01x 1.64x ILA-15.40 Million
2013 -44.16% -396.82% 0.06x 1.78x ILA-17.27 Million
2014 -10.47% -89.71% 0.11x 1.08x ILA-21.69 Million
2015 -22.43% -217.34% 0.09x 1.10x ILA-29.15 Million
2016 -49.60% -4425.00% 0.01x 1.12x ILA-37.86 Million
2017 -126.52% 0.00% 0.00x 1.32x ILA-40.00 Million
2018 -60.68% -126.96% 0.33x 1.43x ILA-26.32 Million
2019 -71.34% 0.00% 0.00x 1.40x ILA-31.17 Million
2020 -24.79% -1484.90% 0.01x 1.15x ILA-41.68 Million
2021 -32.06% -570.05% 0.05x 1.24x ILA-44.87 Million
2022 -43.38% -449.25% 0.08x 1.21x ILA-41.46 Million
2023 -28.61% -56.05% 0.28x 1.85x ILA-25.31 Million
2024 -25.92% -51.07% 0.24x 2.09x ILA-19.72 Million
2025 34.40% 48.57% 0.46x 1.53x ILA25.07 Million

Industry Comparison

This section compares Compugen's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $128,569,333
  • Average return on equity (ROE) among peers: -16.86%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Compugen (CGEN) ILA88.06 Million -63.57% 0.56x $186.23 Million
BioLine RX Ltd (BLRX) $12.77 Million 0.00% 0.61x $9.10 Million
BioLight Life Sciences Ltd (BOLT) $2.72 Million 0.00% 2.72x $7.27 Million
Bonus Biogroup (BONS) $-38.19 Million 0.00% 0.00x $55.11 Million
Can Fite Biopharma Ltd (CANF) $14.79 Million 0.00% 0.48x $3.93 Million
Clal Biotechnology Industries Ltd (CBI) $1.11 Billion 7.88% 0.13x $10.39 Million
DNA Biomed Solns (DNA) $28.18 Million -136.72% 0.30x $33.68 Million
Enlivex Therapeutics Ltd (ENLV) $30.67 Million -22.89% 0.07x $700.05K
Evogene (EVGN) $5.71 Million 0.00% 0.87x $3.66 Million
Kadimastem Ltd (KDST) $-8.06 Million 0.00% 0.00x $22.18 Million

About Compugen

TA:CGEN Israel Biotechnology
Market Cap
$186.23 Million
ILA69.46 Billion ILA
Market Cap Rank
#16898 Global
#202 in Israel
Share Price
ILA734.40
Change (1 day)
-3.41%
52-Week Range
ILA441.40 - ILA924.00
All Time High
ILA6613.00
Categories
Companies in Israel Biotechnology
About

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more